T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting

TL;DR

This review discusses recent advances and new strategies in T cell-based therapies for blood cancers to improve their effectiveness and safety.

Contribution

The paper provides an updated overview of novel targeting strategies to enhance the specificity and efficacy of T cell-redirecting therapies in hematological malignancies.

Findings

Recent developments in TCRT targets for hematological malignancies are summarized.

Novel targeting strategies aim to address challenges like on-target/off-tumor toxicities.

Preclinical and early-stage clinical data are reviewed to guide future TCRT development.

Abstract

T cell-redirecting therapies (TCRTs), such as chimeric antigen receptor (CAR) or T cell receptor (TCR) T cells and T cell engagers, have emerged as a highly effective treatment modality, particularly in the B and plasma cell-malignancy setting. However, many patients fail to achieve deep and durable responses; while the lack of truly unique tumor antigens, and concurrent on-target/off-tumor toxicities, have hindered the development of TCRTs for many other cancers. In this review, we discuss the recent developments in TCRT targets for hematological malignancies, as well as novel targeting strategies that aim to address these, and other, challenges.

In this review, Chapman and Anderson summarize preclinical and early-stage clinical targets for T cell-redirecting therapies (TCRTs) in hematological malignancies and discuss novel targeting strategies that will improve the specificity of future TCRT therapies to enable safer and more effective treatment.

Figures